EX-10.38-K·CIK 1175151·0001104659-26-130442

Third Amendment to Loan Documents

View original filing on SEC EDGAR → ·  seen Nov 20, 2026, 08:56 EST

Exhibit 10.3

THIRD AMENDMENT TO LOAN Documents

This Third Amendment to Loan Documents (this “Amendment”) is entered into as of November 19, 2026 (the “Third Amendment Effective Date”), by and among AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (“Agent”**), AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (“Avenue”), AVENUE VENTURE OPPORTUNITIES FUND II, L.P., a Delaware limited partnership (“Avenue 2”; together with Avenue, each “Lender” and, collectively, “Lenders”) and CYTOSORBENTS CORPORATION, a Delaware corporation (“Borrower”**).

RECITALS

Agent, Lenders and Borrower are parties to those certain Loan Documents dated as of June 28, 2024, including that certain Loan and Security Agreement (as amended from time to time, the “Loan Agreement”) and Supplement to Loan and Security Agreement (as amended from time to time, the “Supplement”; and together with the Loan Agreement, the “Loan Documents”). The parties desire to amend the Loan Documents in accordance with the terms of this Amendment. Capitalized terms used but not defined herein have the meaning assigned to such terms in the Loan Agreement or Supplement, as the case may be.

NOW, THEREFORE, the parties agree as follows:

1.            The following terms and their respective definitions are hereby either amended and restated, or if applicable added, in their entirety to Part 1 of the Supplement as follows:

**“Commitment” **means, subject to the terms and conditions set forth in the Loan and Security Agreement and this Supplement, Lenders’ commitment to make Growth Capital Loans to Borrower up to an aggregate original principal amount of Seventeen Million Five Hundred Thousand Dollars ($17,500,000), with Four Million Five Hundred Thousand Dollars ($4,500,000) funded by Avenue and Ten Million Five Hundred Thousand Dollars ($10,500,000) funded by Avenue 2 on the Closing Date (“Tranche 1”) and Seven Hundred Fifty Thousand Dollars ($750,000) funded by Avenue and One Million Seven Hundred Fifty Thousand Dollars ($1,750,000) funded by Avenue 2 in November 2025 (“Tranche 2A”).

“Interest-only Period” means the period commencing on the Closing Date and continuing until March 31, 2028; provided, however, that such period shall be extended for three (3) months if as of the last day of the Interest-only Period then in effect Borrower has achieved FDA Marketing Approval; provided, further, that the Interest-only Period shall not exceed fifty-four (54) months; provided, further, however, that no extension of the Interest-only Period shall be available if as of the last day of the Interest-only Period then in effect an Event of Default shall have occurred and be continuing.

“Maturity Date” means July 1, 2028.

**“Trading Price” **means $4.94.

2.            Section 1 of Part 2 of the Supplement hereby is amended and restated in its entirety to read as follows:

“1.         Additional Condition(s) Precedent Regarding Growth Capital Loan Commitments. In addition to the satisfaction of all of the other applicable conditions precedent specified in Sections 4.1 and 4.2 of the Loan and Security Agreement and this Supplement, each Lender’s obligation to fund Tranche 2A of its Commitment of Growth Capital Loans is subject to receipt by Lender of evidence that the following conditions precedent have been satisfied, as determined by Lender in its sole discretion:

(i)            [reserved]; and

(ii)            no Event of Default shall have occurred and be continuing.

-1-

Subject to satisfaction of the conditions precedent specified in Sections 4.1 and Section 4.2 of the Loan and Security Agreement and this Supplement, each Lender agrees to make Growth Capital Loans to Borrower under Lender’s Commitment from time to time from and after the Closing Date up to and including the Termination Date in an aggregate, original principal amount up to, but not exceeding, the then-unfunded portion of such Lender’s Commitment.”

3.            Section 2 of Part 2 of the Supplement hereby is amended and restated in its entirety to read as follows:

“2.         Prepayment. The Growth Capital Loans may be prepaid as provided in this Section 2 only. Borrower may prepay outstanding Growth Capital Loans in whole or in part, at any time upon no less than five (5) Business Days’ prior written notice to the Lenders, by tendering to each Lender a cash payment in respect of such Loans in an amount determined by such Lender equal to the sum of: (i) the outstanding principal amount of such Loans being prepaid, which such amount shall be at least Two Million Dollars ($2,000,000); (ii) the accrued and unpaid interest on such Loans as of the date of prepayment; (iii) the Prepayment Fee applicable to the principal amount of Loan being prepaid; and (iv)(x) in the case of a prepayment in full, the Final Payment (less any amount of the Final Payment prepaid pursuant to Part 2, Section 2(iv)(y) below in connection with any partial prepayment of the Loans), and (y) in the case of any partial prepayment, a portion of the Final Payment in an amount equal to four and one-half of one percent (4.50%) of the principal amount of Loans being prepaid; provided that, if a Lender has not yet exercised its rights under Section 3(d) hereof, Borrower shall provide written notice of prepayment at least ten (10) days in advance of the proposed prepayment date and such Lender shall have the option, with respect to each Conversion Option, to exercise its rights pursuant to Section 3(d) hereof by delivering written notice to Borrower at least two (2) Business Days in advance of the proposed prepayment date. In the event Borrower elects to partially prepay the Growth Capital Loans and the outstanding principal balance after such prepayment will be less than the amount of the Conversion Option, such prepayment shall reduce the amount of the Conversion Option with the highest Conversion Price first. All rights to Conversion shall terminate on loan payoff.”

2

4.            Section 3(d) of Part 2 of the Supplement hereby is amended and restated in its entirety to read as follows:

“(d)       Conversion Right. Lenders shall have the right, in their respective discretion, but not the obligation, (i) at any time and from time to time, while the Loan is outstanding, to convert an aggregate repayment amount of up to Three Million Dollars ($3,000,000) of the principal amount of the outstanding Growth Capital Loans (the “First Conversion Option”) into Borrower’s unrestricted, freely tradeable common stock at a price per share equal to one hundred forty percent (140.00%) of the Trading Price (the price per share, the “First Conversion Price;” the exercise of the First Conversion Option, a “First Conversion”) and (ii) upon the earlier of (1) the date Borrower has achieved the FDA Marketing Approval and (2) January 1, 2028, in each case while the Loan is outstanding, to convert an aggregate amount of up to Three Million One Hundred Twenty Five Thousand Dollars ($3,125,000) of the principal amount of the outstanding Growth Capital Loans (the “Second Conversion Option”, and collectively with the First Conversion Option, each a “Conversion Option”) into Borrower’s unrestricted, freely tradeable common stock at a price per share equal to one hundred seventy five percent (175.00%) of the Trading Price (the price per share, the “Second Conversion Price”, and collectively with the First Conversion Price, each a “Conversion Price”; the exercise of such Second Conversion Option, a “Second Conversion”, and collectively with the First Conversion, each a “Conversion”). Each Conversion Option will be exercised by such Lender delivering a written, signed conversion notice to the Borrower in accordance with this Section 3(d) (each, a “Conversion Notice”) which will include (i) the date of which the conversion notice is given, (ii) a statement to the effect that the Lender is exercising such Conversion Option, (iii) the amount in respect of which such Conversion Option is being exercised and the number of shares issued and (iv) a date on which the allotment and issuance of the shares is to take place, subject to the provisions below. In the event Borrower prepays the Loan pursuant to Section 2, Borrower shall provide to Lenders written notice of prepayment at least ten (10) days in advance of the proposed prepayment date and such Lender shall have the option to exercise each Conversion Option pursuant to this Section 3(d) by delivering written notice to Borrower at least two (2) Business Days in advance of the proposed prepayment date; provided that, if Borrower partially prepays the Loan pursuant to Section 2 and the outstanding principal balance of the Loans will be less than the amount of the Conversion Options after giving effect to such prepayment, such prepayment shall reduce the amount of the Conversion Option with the highest Conversion Price first. Each Conversion Option will not survive the expiration or other termination of the Loan and Security Agreement and shall otherwise terminate when the Loan is repaid in full. Notwithstanding any provision to the contrary, to the extent Borrower is unable to issue all of the unrestricted, freely tradeable shares issuable on Conversion (“Conversion Shares”) on the date proposed in the Conversion Notice in compliance with applicable securities laws in connection with a shortfall of unrestricted, freely tradeable shares registered and available for issuance under Borrower’s then-effective shelf registration statement (with satisfactory evidence of such shortfall provided from Borrower to Agent), Borrower shall (A) notify Lenders in writing promptly (and in any event within one (1) Business Day) after receipt of such Conversion Notice of such shortfall and the number of Conversion Shares then registered and available for issuance under such shelf registration statement (a “Deferral Notice”), and (B) on the date proposed in the Conversion Notice, issue and deliver to Lenders all Conversion Shares subject to such Conversion Notice that are then registered and available for issuance under such shelf registration statement (the “Available Conversion Shares”), whereupon the principal amount of the outstanding Growth Capital Loans shall be reduced by the portion thereof converted into such Available Conversion Shares at the applicable Conversion Price. Within forty-eight (48) hours after delivery of the Available Conversion Shares, Lenders may elect, in their sole discretion, by written notice to Borrower, either (x) to receive the remaining Conversion Shares subject to such Conversion Notice that are not Available Conversion Shares (the “Deferred Conversion Shares”) or (y) to withdraw such Conversion Notice solely with respect to the Deferred Conversion Shares, in which case such Conversion Notice (solely as to the Deferred Conversion Shares) shall be deemed void ab initio, and the principal amount of the outstanding Growth Capital Loans corresponding to the Deferred Conversion Shares shall remain outstanding and subject to the applicable Conversion Option. If Lenders do not deliver such written notice within such forty-eight (48) hour period, Lenders shall be deemed to have elected the option set forth in clause (y). No election (or deemed election) by Lenders pursuant to this Section 3(d) shall result in any penalty, fee, forfeiture, reduction of any Conversion Option or other adverse consequence to Lenders; provided that, if Lenders elect to receive the Deferred Conversion Shares, Borrower may defer the issuance of such Deferred Conversion Shares for a period of up to sixty (60) days after receipt of the applicable Conversion Notice in order to file with the SEC a registration statement on Form S-3 (or other available form) (a "Resale Registration Statement") covering the resale by Avenue of such Deferred Conversion Shares. Borrower shall use commercially reasonable efforts to cause such Resale Registration Statement to be declared effective within ninety (90) days after receipt of such Conversion Notice, and shall use commercially reasonable efforts to keep the Resale Registration Statement effective until the earlier of the date on which all such Deferred Conversion Shares have been sold and the date on which such Deferred Conversion Shares may be sold without restriction under Rule 144 under the Securities Act. Lenders shall furnish such information regarding itself and its intended method of distribution as Borrower may reasonably request in connection therewith. Borrower's failure to satisfy any timing requirement in this Section 3(d) shall not constitute a Default or Event of Default, and Lenders’ sole remedy shall be specific performance of Borrower's obligations hereunder.”

3

5.            A new Section 3(e) hereby is added to the Supplement as follows:

“(e)          Conversion and Exercise Limitations. Lender shall not have the right to exercise any Conversion Option or any Warrant, and any such exercise shall be null and void and treated as if never made, to the extent that after giving effect to the conversion or exercise set forth on the applicable conversion notice or notice of exercise (each, an “Exercise Notice”) , such Lender (together with such Lender’s Affiliates, and any Persons acting as a group together with such Lender or any of the such Lender’s Affiliates, the “Attribution Parties”) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of common stock beneficially owned by Lender and its Attribution Parties shall include the number of shares of common stock issuable upon Lender’s exercise of any Conversion Option or Warrant with respect to which such determination is being made, but shall exclude the number of shares of common stock which are issuable upon (i) conversion of the remaining, unconverted principal amount of any outstanding Growth Capital Loans beneficially owned by Lender or any of its Attribution Parties, (ii) exercise of the remaining, unexercised portion of any Warrant beneficially owned by Lender or any of its Attribution Parties, and (iii) exercise or conversion of the unexercised or unconverted portion of any other securities of Borrower subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by Lender or any of its Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 3(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 3(e) applies, the determination of whether Lender can exercise any Conversion Option or Warrant (in relation to other securities owned by Lender together with any Attribution Parties) shall be in the sole discretion of Lender, and the submission of an Exercise Notice shall be deemed to be Lender’s determination of whether Lender may exercise such Conversion Option or Warrant (in relation to other securities owned by Lender together with any Attribution Parties) in each case subject to the Beneficial Ownership Limitation. Borrower shall have no obligation to verify or confirm such determination and shall have no liability for any Exercise Notice delivered in breach of this Section 3(e), and no issuance of shares of common stock in reliance on an Exercise Notice shall constitute a Default or Event of Default. Any portion of an Exercise Notice that would result in Lender exceeding the Beneficial Ownership Limitation shall be void, and the corresponding principal amount shall remain outstanding and subject to the applicable Conversion Option or the corresponding portion of the Warrant shall remain outstanding and exercisable in accordance with its terms, as applicable. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 3(e), in determining the number of outstanding shares of common stock, Lender may rely on the number of outstanding shares of common stock as stated in the most recent of the following: (i) Borrower’s most recent periodic or annual report filed with the SEC, as the case may be, (ii) a more recent public announcement by Borrower, or (iii) a more recent written notice by Borrower or Borrower’s transfer agent setting forth the number of shares of common stock outstanding. Upon the written request of Lender, Borrower shall within two Trading Days confirm in writing to Lender the number of shares of common stock then outstanding as reflected in Borrower’s records or the records of its transfer agent. In any case, the number of outstanding shares of common stock shall be determined after giving effect to the conversion or exercise of securities of Borrower, including any Conversion Option or Warrant, by Lender or its Attribution Parties since the date as of which such number of outstanding shares of common stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon exercise of any Conversion Option or Warrant. By written notice to the Borrower, Lender may from time to time increase or decrease the Beneficial Ownership Limitation to any other percentage specified in such notice; provided that (i) any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Borrower, and (ii) any such increase or decrease will apply only to such Lender.

Notwithstanding anything to the contrary herein, Borrower shall not issue, and no Lender shall be entitled to receive, upon exercise of the Conversion Options or the Warrants any shares of common stock to the extent that such issuance, when aggregated with all other shares of common stock issued upon exercise of the Conversion Options and the Warrants, would exceed 19.99% of the shares of common stock outstanding on the Third Amendment Effective Date (the “Exchange Cap”), unless Borrower has obtained stockholder approval of such issuance in accordance with the rules of the principal trading market on which the common stock is listed. Upon Lender’s written request, Borrower shall use its commercially reasonable efforts to seek such stockholder approval at its next annual meeting of stockholders, and failure to obtain such approval shall not constitute a Default or Event of Default. Any principal amount that cannot be converted as a result of the Exchange Cap shall remain outstanding as a Growth Capital Loan and shall be payable in accordance with the Loan Documents, and any portion of a Warrant that cannot be exercised as a result of the Exchange Cap shall remain outstanding and exercisable in accordance with its terms upon receipt of such stockholder approval.

Any principal amount of the Growth Capital Loans converted pursuant to Section 3(d) shall be applied to reduce each installment payment of the outstanding principal of the Loans held by the converting Lender on a pro rata basis, and, no Prepayment Fee or Final Payment (or any portion thereof) shall be payable with respect to such amount so converted, and the Final Payment shall be reduced proportionately to reflect any such conversion.”

4

6.            Section 5.13 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

“5.13     Cash Burn. Borrower shall achieve Cash Burn for each Testing Period, as tested on a monthly basis beginning with the Testing Period ending March 31, 2026 and ending on the FDA Marketing Approval Date, of no more than Two Million Dollars ($2,000,000.00) (the “Cash Burn Threshold”); provided that for each Testing Period from the Third Amendment Effective Date through and including December 31, 2026, the Cash Burn Threshold shall be Three Million Two Hundred Thousand Dollars ($3,200,000.00).”

7.

7.1            Notwithstanding anything else herein, on the Third Amendment Effective Date, (a) Borrower shall pay to Avenue Venture Opportunities Fund, L.P. the amount of Three Million Three Hundred Twenty Two Thousand Five Hundred Dollars ($3,322,500.00), which amount shall be applied to the outstanding principal of the Loans held by Avenue Venture Opportunities Fund, L.P., together with associated Prepayment Fee and Final Payment as referenced below, and shall consist of (i) Three Million Dollars ($3,000,000.00) in respect of principal payment, (ii) Fifty Two Thousand Five Hundred Dollars ($52,500.00) as a Prepayment Fee and (iii) Two Hundred Seventy Thousand Dollars ($270,000.00) in respect of the Final Payment (the “Third Amendment Final Payment”), and (b) the remaining outstanding principal amount of the Loans held by Avenue Venture Opportunities Fund, L.P., being Two Million Two Hundred Fifty Thousand Dollars ($2,250,000.00) (the “Share Repayment Amount”), shall be repaid by Borrower in shares of Borrower’s common stock (the “Share Repayment Shares”) at a price per share equal to the price per share at which shares of Borrower’s common stock are issued and sold to the purchasers under that certain Securities Purchase Agreement, dated November 19, 2026 (the “Securities Purchase Agreement”), by and among the Borrower and the purchasers party thereto, in Borrower’s equity financing contemplated thereby (the “Share Repayment Price”; such repayment , the “Share Repayment”). The number of Share Repayment Shares to be issued to Avenue Venture Opportunities Fund, L.P. shall equal the Share Repayment Amount divided by the Share Repayment Price, rounded up to the nearest whole share. The Share Repayment Shares shall be issued in two portions: (x) Share Repayment Shares in respect of One Million Dollars ($1,000,000.00) of the Share Repayment Amount (the "Registered Repayment Shares") shall be issued pursuant to Borrower's effective registration statement on Form S-3 and shall be unrestricted and freely tradeable upon issuance, and (y) the balance of the Share Repayment Shares, in respect of One Million Two Hundred Fifty Thousand Dollars ($1,250,000.00) of the Share Repayment Amount (the "Unregistered Repayment Shares"), shall be issued in a transaction exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), shall bear a customary restrictive legend until registered for resale pursuant to Section 7.4 or eligible for resale without restriction, and shall be subject to the registration rights set forth in Section 7.4. Borrower shall issue the Share Repayment Shares to Avenue Venture Opportunities Fund, L.P. in book-entry form substantially concurrently with the closing of the equity financing under the Securities Purchase Agreement. Upon the issuance of the Share Repayment Shares, the Share Repayment Amount shall be deemed repaid in full and shall no longer be outstanding. For the avoidance of doubt, the Share Repayment is made pursuant to this Section 7.1 and not pursuant to Section 3(d) of Part 2 of the Supplement, and shall not constitute an exercise of, or reduce the amount available under, either Conversion Option. The Share Repayment Amount is separate and distinct from, and shall not reduce or otherwise affect, the principal amount of the Growth Capital Loans subject to the Conversion Options. After giving effect to such payment and the Share Repayment, the outstanding principal balance of the Loans shall be equal to Zero Dollars ($0.00) and Twelve Million Two Hundred Fifty Thousand Dollars ($12,250,000) for Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P., respectively and the remaining outstanding amount of the Final Payment is Six Hundred Thirty Thousand Dollars ($630,000), as a result of the subtraction of the Third Amendment Final Payment from 4.50% of the original Commitment amount of Twenty Million Dollars ($20,000,000.00).

7.2            [Reserved]

5

7.3            In consideration of Avenue’s agreement to the Share Repayment, Borrower shall pay to Avenue an additional final payment in the amount of Two Hundred Fifty Thousand Dollars ($250,000.00) (the “Additional Final Payment”), which amount shall be due and payable on July 1, 2028 (or, if earlier, the date on which the Obligations are repaid in full or otherwise become due and payable, whether by acceleration or otherwise) (the “Additional Final Payment Date”); provided, however, that the Additional Final Payment shall be waived and shall not be payable if, as of the Additional Final Payment Date, Avenue has achieved a net profit from the sale of the Share Repayment Shares of at least three hundred percent (300%) (the “Share Repayment Net Profit”), as determined by Avenue in its reasonable discretion. Notwithstanding anything to the contrary herein or in any other Loan Document, the Additional Final Payment and the Share Repayment Net Profit (including the three hundred percent (300%) threshold described above) shall apply solely to the Share Repayment Amount repaid to Avenue pursuant to Section 7.1 hereunder and the Share Repayment Shares issued in respect thereof, and shall not apply to, and shall be determined without regard to, (i) any principal amount of the Growth Capital Loans held by, or converted by, Avenue 2 (including pursuant to any Conversion Option, which Conversion Options cover up to Six Million One Hundred Twenty Five Thousand Dollars ($6,125,000) in the aggregate), or any shares of common stock issued in respect thereof, or (ii) any Warrant or any shares of common stock issued upon the exercise of any Warrant.

7.4            Borrower shall (a) within sixty (60) days after the Third Amendment Effective Date, file with the SEC a Resale Registration Statement covering the resale by Avenue of the Unregistered Repayment Shares, (b) use commercially reasonable efforts to cause the Resale Registration Statement to be declared effective within ninety (90) days after the Third Amendment Effective Date, and (c) use commercially reasonable efforts to keep the Resale Registration Statement effective until the earlier of the date on which all Unregistered Repayment Shares have been sold and the date on which such shares may be sold without restriction under Rule 144 under the Securities Act. Avenue shall furnish such information regarding itself and its intended method of distribution as Borrower may reasonably request in connection therewith. Borrower's failure to satisfy any timing requirement in this Section 7.4 shall not constitute a Default or Event of Default, and Avenue's sole remedy shall be specific performance of Borrower's obligations hereunder.

8.            No course of dealing on the part of Agent or any Lender, nor any failure or delay in the exercise of any right by Agent or any Lender, shall operate as a waiver thereof, and any single or partial exercise of any such right shall not preclude any later exercise of any such right. Agent or any Lender’s failure at any time to require strict performance by Borrower of any provision shall not affect any right of Agent or any Lender thereafter to demand strict compliance and performance. Any suspension or waiver of a right must be in writing signed by an officer of Agent or Lender.

9.            Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Loan Documents (as defined in the Agreement). The Loan Documents, as amended hereby, shall be and remain in full force and effect in accordance with their respective terms and hereby are ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Agent or any Lender under the Loan Documents, as in effect prior to the date hereof.

10.            As a condition to the effectiveness of this Amendment, Agent shall have received, in form and substance reasonably satisfactory to Agent, the following:

(a)            this Amendment, duly executed by Borrower;

(b)            payment by Borrower to Agent of Three Million Three Hundred Twenty Two Thousand Five Hundred Dollars ($3,322,500.00) to be applied in accordance with Section 7 of this Amendment;

(c)            evidence that the Share Repayment Shares have been issued to Avenue in book-entry form, including a copy of the irrevocable instructions delivered by Borrower to its transfer agent with respect thereto;

(d)            all reasonable Agent and Lender expenses incurred through the date of this Amendment; and

(e)            such other documents, and completion of such other matters, as Agent may reasonably deem necessary or appropriate.

6

11.            This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.

[Balance of Page Intentionally Left Blank]

7

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written.

BORROWER:
CYTOSORBENTS CORPORATION
By: /s/ Phillip P. Chan
Name: Phillip P. Chan, MD, Ph.D.
Title: Chief Executive Officer
CYTOSORBENTS MEDICAL, INC.
By: /s/ Phillip P. Chan
Name: Phillip P. Chan, MD, Ph.D.
Title: Chief Executive Officer
AGENT:
AVENUE CAPITAL MANAGEMENT II, L.P.
By: Avenue Capital Management II GenPar, LLC
Its: General Partner
By: /s/ Sonia Gardner
Name: Sonia Gardner
Title: Member
LENDERS:
AVENUE VENTURE OPPORTUNITIES FUND, L.P.
By:     Avenue Venture Opportunities Partners, LLC
Its:     General Partner
By: /s/ Sonia Gardner
Name: Sonia Gardner
Title: Authorized Signatory
AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
By:     Avenue Venture Opportunities Partners II, LLC
Its:     General Partner
By: /s/ Sonia Gardner
Name: Sonia Gardner
Title: Authorized Signatory
Back to all agreements